Candidate Galeno 2024
Futibatinib (Lytgobi®) from Taiho Oncology Europe is a novel tyrosine kinase inhibitor indicated for the second-line treatment of locally advanced or metastatic cholangiocarcinoma with genetically altered fibroblast growth factor receptor 2 (FGFR2).